An observational study in Acute Ischemic Stroke, sponsored by Supergene, LLC. Completed at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by Supergene, LLC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Ischemic Stroke with a site in Russia — 13 open to participants now, 13 under way, 2 of them phase 3. Ischemic Stroke · Russia.
Among the 17 studies in Ischemic Stroke with a site in Russia, this one is the only one that started in 2021, is one of 8 observational ones, and was the 8th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →13 of the 17 studies in Ischemic Stroke with a site in Russia are open now. Recruiting first, the newest first:
Supergene, LLC · Sites in Russia
Ages 18+
Pharmasoft · Sites in Russia
Ages 18–90 · Healthy volunteers
Tatchempharmpreparaty, JSC · Sites in Russia
Ages 35–80
Pirogov Russian National Research Medical University · Sites in Russia
Ages 40–80
POLYSAN Scientific & Technological Pharmaceutical Company · Sites in Russia
Ages 18+
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23,250 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 120 across the 9 interventional studies, 448 across the 8 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
Supergene, LLC is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Supergene, LLC has 3 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
6 of the studies in Ischemic Stroke with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07912151Samara State Medical UniversityDynamic Stabilometry Combined With Transcranial Direct Current Stimulation for Balance and Motor Recovery After Ischemic Stroke | 2026-12-28 |
| NCT06175715Pirogov Russian National Research Medical UniversityGeneral Versus Regional Anesthesia for Carotid Endarterectomy at Acute Ischemic Stroke Trial | 2026-12-31 |
| NCT07520630Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports MedicineNeurophysiological Markers for Prediction of Rehabilitation Outcomes After Ischemic Stroke | 2027-03 |
| NCT07575984PharmasoftMexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke | 2027-04 |
| NCT07083986Pirogov Russian National Research Medical UniversityCarotid Endarterectomy Versus Stenting in Patients With Acute Stage of Ischemic Stroke. | 2027-05-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 17 studies in Ischemic Stroke with a site in Russia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of FORPI Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with acute ischemic stroke in routine clinical practice.
Acute ischemic stroke is caused by the formation of blood clot in the major vessel which gives blood supply to a certain part of the brain. New approaches to the treatment of acute ischemic stroke include the use of modern highly effective methods of reperfusion of brain tissue in the first hours of the disease, aimed at restoring blood flow in the affected vessel, which helps prevent the development of irreversible damage to brain tissue or reduce its volume, i.e. minimize the severity of residual neurological deficit.
In December 2019, a multicenter, open-label, randomized non-inferiority trial of the efficacy and safety of the non-immunogenic staphylokinase (Fortelyzin®) compared with alteplase (Actilyse®) in patients with acute ischemic stroke (FRIDA) was completed (NCT03151993).
The primary efficacy outcome in both the non-immunogenic staphylokinase and alteplase groups, as well as in their subgroups depending on age, body weight, onset to treatment time, baseline NIHSS, localization and subtype of acute ischemic stroke showed that the non-immunogenic staphylokinase administered as a single bolus in a dose of 10 mg regardless of body weight is non-inferior to alteplase, administered as a bolus infusion at a dose of 0.9 mg/kg body weight, at a maximum dose of 90 mg in the treatment of patients with acute ischemic stroke within 4.5 hours from the symptoms onset. The non-immunogenic staphylokinase has demonstrated high safety profile. The indication "acute ischemic stroke" is included in the Instructions for medical use of the non-immunogenic staphylokinase. In routine clinical practice, the non-immunogenic staphylokinase is used for acute ischemic stroke treatment since 2021.
The aim of FORPI Registry is to study the safety and efficacy of the non-immunogenic staphylokinase in patients with acute ischemic stroke in routine clinical practice.
Men and women aged 18 years and older with verified acute ischemic stroke, less than 4.5 h symptoms onset to treatment, who received a single intravenous bolus of the non-immunogenic staphylokinase (10 mg).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: non-immunogenic staphylokinase
Drug: Non-immunogenic staphylokinase
Drug: non-immunogenic staphylokinase 10 mg as a single intravenous bolus Other Names: Fortelyzin®
Also known as: Fortelyzin®
Modified Rankin Scale (mRS) score of 0-2 on day 90 after drug administration
The number of patients with Modified Rankin Scale (mRS) scores 0-2 on day 90 after drug administration, where 0 - No symptoms, 1 - No significant disability, 2 - Slight disability.
Time frame: day 90 after drug administration
mRS score on day 90 after drug administration
The median of mRS score on day 90 after drug administration, where: 0 - No symptoms, 1 - No significant disability, 2 - Slight disability, 3 - Moderate disability, 4 - Moderately severe disability, 5 - Severe disability, 6 - Dead.
Time frame: day 90 after drug administration
The National Institutes of Health Stroke Scale (NIHSS) at 24 hours after drug administration
The median of The National Institutes of Health Stroke Scale (NIHSS) at 24 h after drug administration, where: 0 - No stroke symptoms, 1-4 - Minor stroke, 5-15 - Moderate stroke, 16-20 - Moderate to severe stroke, 21-42 - Severe stroke.
Time frame: 24 hours after drug administration
NIHSS on day 7 after drug administration
The median of NIHSS on discharge
Time frame: day 7 after drug administration
All-cause mortality
The number of death from any causes during 90 days after drug administration
Time frame: day 90 after drug administration
Intracranial haemorrhage
The number of intracranial haemorrhage during 90 days after drug administration
Time frame: day 90 after drug administration
Symptomatic intracerebral haemorrhage
The number of symptomatic intracranial haemorrhage (sICH) defined as an NIHSS decline of ≥4 points compared with baseline NIHSS or the lowest NIHSS value or death between baseline and 7 days, associated with any haemorrhage judged by core lab evaluation to be responsible for the decline. Blood may be anywhere in the intracranial space including in the intraventricular, intraparenchymal and/or subarachnoid space (modified ECASS III definition) during 90 days after drug administration
Time frame: day 90 after drug administration
Major bleedings
The number of major bleedings (according to BARC classification type 3 and 5) during 90 days after drug administration
Time frame: day 90 after drug administration
Thrombectomy
The number of thrombectomy during 90 days after drug administration
Time frame: day 90 after drug administration
Allergic reactions
The number of allergic reactions during 90 days after drug administration
Time frame: day 90 after drug administration
Pulmonary embolism
The number of pulmonary embolism during 90 days after drug administration
Time frame: day 90 after drug administration
Plan to share: No
Ran from Mar 2021 to primary completion in Dec 2024, 45 months.
Of 42 industry-sponsored observational studies under Ischemic Stroke, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 45 months is above that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supergene, LLC